Phase I and preliminary phase 0 results of ABTC 1801: A multi-arm clinical trial of the PARP inhibitor pamiparib (BGB290) with very low dose metronomic temozolomide in recurrent IDH mutant gliomas Meeting Abstract


Authors: Schiff, D.; Bindra, R.; Li, J.; Ye, X.; Ellingson, B.; Walbert, T.; Campian, J.; Nabors, L. B.; Lieberman, F.; Ozer, B.; Desai, A.; Omuro, A.; Wen, P.; Desideri, S.; Fisher, J.; Grossman, S.
Abstract Title: Phase I and preliminary phase 0 results of ABTC 1801: A multi-arm clinical trial of the PARP inhibitor pamiparib (BGB290) with very low dose metronomic temozolomide in recurrent IDH mutant gliomas
Meeting Title: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Journal Title: Neuro-Oncology
Volume: 23
Issue: Suppl. 6
Meeting Dates: 2021 Nov 18-21
Meeting Location: Boston, MA
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2021-11-01
Start Page: vi63
Language: English
ACCESSION: WOS:000757356200245
PROVIDER: wos
DOI: 10.1093/neuonc/noab196.243
Notes: Meeting Abstract: CTNI-18 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Antonio Marcilio Padula Omuro
    204 Omuro